Patents by Inventor Weiguo Xiang

Weiguo Xiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059704
    Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu
  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059711
    Abstract: Described herein are compounds of Formula I and conjugates of Formula I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Yuk-Ming Siu, Rohan Rej, Ranjan Kumar Acharyya, Weiguo Xiang, Longchuan Bai
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND
    Publication number: 20230357249
    Abstract: The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 9, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao, Mingliang Wang, Rohan Rej
  • SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20230257365
    Abstract: The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 17, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20230233690
    Abstract: The present disclosure provides compounds represented by Formula I: A-L-B1 and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: July 27, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Lijie Zhao
  • CEREBLON E3 LIGASE INHIBITORS
    Publication number: 20220388978
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R2a, R2b, R2c, R2d, R3, R13, and Z are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are cereblon (CRBN) ubiquitination inhibitors or monofunctional synthetic intermediates that can be used to prepare PROTAC molecules. CRBN ubiquitination inhibitors and PROTAC molecules are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 8, 2022
    Inventors: Shaomeng Wang, Tianfeng Xu, Mingliang Wang, Jiantao Hu, Xi Han, Weiguo Xiang, Rohan Rej
  • SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220380368
    Abstract: The present disclosure provides compounds represented by Formula (I) and the salts or solvates thereof, wherein R3a, E, L, A1, B1, X1, X2, Z1, and Z2 are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Bukeyan Miao, Chong Qin, Lijie Zhao, Jianfeng Lu, Tianfeng Xu, Chao-Yie Yang
  • FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS
    Publication number: 20220356192
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: April 12, 2021
    Publication date: November 10, 2022
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220081435
    Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 17, 2022
    Inventors: Shaomeng Wang, Xin Han, Chao Wang, Chong Qin, Weiguo Xiang, Tianfeng Xu, Chao-Yie Yang
  • BET bromodomain protein degraders with cleavable linkers
    Patent number: 11267822
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: March 8, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
  • Fused 1,4-diazepines as BET protein degraders
    Patent number: 10975093
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20210002289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: August 31, 2020
    Publication date: January 7, 2021
    Inventors: Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • BET Bromodomain Protein Degraders with Cleavable Linkers
    Publication number: 20200277305
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 3, 2020
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
  • Monofunctional intermediates for ligand-dependent target protein degradation
    Patent number: 10759808
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS
    Publication number: 20190263827
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 29, 2019
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20190119289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang